中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
8期
1237-1238,1240
,共3页
莲芪胶囊%化疗%食道癌%DF方案
蓮芪膠囊%化療%食道癌%DF方案
련기효낭%화료%식도암%DF방안
Lianqi capsule%Chemotherapy%Esophageal cancer%DF chemotherapy program
目的：探讨莲芪联合化学治疗(化疗)治疗中晚期食道癌的临床效果。方法：选择笔者所在医院2008年2月～2010年10月期间住院的中晚期食道癌患者130例，随机分为对照组和治疗组，分别64例、66例，两组均应用化疗DF方案，同时治疗组加服莲芪胶囊，对照组加服平消胶囊。结果：治疗组临床疗效略高于对照组，但两组总有效率比较差异无统计学意义(P=0.24)。治疗组1年生存率、2年生存率分别为83.07%、55.38%，均显著高于对照组(P值分别为0.043，0.040)。两组治疗后CD4+、CD4+/CD8+值、NK细胞均较治疗前增高。但治疗组各项指标增高幅度显著，与对照组比较差异均具有统计学意义(P<0.05)。结论：中晚期食道癌治疗在化疗基础上应用莲芪胶囊，不但能增强患者机体免疫功能，还能提高化疗的临床疗效，延长生存期。
目的：探討蓮芪聯閤化學治療(化療)治療中晚期食道癌的臨床效果。方法：選擇筆者所在醫院2008年2月～2010年10月期間住院的中晚期食道癌患者130例，隨機分為對照組和治療組，分彆64例、66例，兩組均應用化療DF方案，同時治療組加服蓮芪膠囊，對照組加服平消膠囊。結果：治療組臨床療效略高于對照組，但兩組總有效率比較差異無統計學意義(P=0.24)。治療組1年生存率、2年生存率分彆為83.07%、55.38%，均顯著高于對照組(P值分彆為0.043，0.040)。兩組治療後CD4+、CD4+/CD8+值、NK細胞均較治療前增高。但治療組各項指標增高幅度顯著，與對照組比較差異均具有統計學意義(P<0.05)。結論：中晚期食道癌治療在化療基礎上應用蓮芪膠囊，不但能增彊患者機體免疫功能，還能提高化療的臨床療效，延長生存期。
목적：탐토련기연합화학치료(화료)치료중만기식도암적림상효과。방법：선택필자소재의원2008년2월～2010년10월기간주원적중만기식도암환자130례，수궤분위대조조화치료조，분별64례、66례，량조균응용화료DF방안，동시치료조가복련기효낭，대조조가복평소효낭。결과：치료조림상료효략고우대조조，단량조총유효솔비교차이무통계학의의(P=0.24)。치료조1년생존솔、2년생존솔분별위83.07%、55.38%，균현저고우대조조(P치분별위0.043，0.040)。량조치료후CD4+、CD4+/CD8+치、NK세포균교치료전증고。단치료조각항지표증고폭도현저，여대조조비교차이균구유통계학의의(P<0.05)。결론：중만기식도암치료재화료기출상응용련기효낭，불단능증강환자궤체면역공능，환능제고화료적림상료효，연장생존기。
To observe the clinical efficacy of Lianqi Capsule combined with chemotherapy in the treatment of 66 cases of advanced esophageal cancer.Methods:130 patients with advanced esophageal cancer in the hospital where the author in from February 2008 to October 2010 were randomly divided into control and treatment groups. Each group had 64 cases and 66 cases respectively. Both groups were given DF chemotherapy programs, while treatment group were given additional Lianqi capsules and the control group were given additional Pingxiao capsules.Results:The clinical efficacy of the treatment group was slightly higher than that of the control group, but there was no significant difference between the total effective rate (P=0.24).The 1-year and 2-year survival rates of the treatment group were 83.07% and 55.38%,which were significantly higher than that of the control group(P=0.043 & 0.040).The value of CD4+,CD4+/CD8+ and the number of NK cells was higher after treatment. The indexes of the treatment group increased significantly compared with the control group,and there were statistically significant differences (P<0.05).Conclusion:The therapy that chemotherapy combined with Lianqi Capsules in the treatment of advanced esophageal cancer can not only enhance immune function in patients, but also improve the clinical efficacy of chemotherapy and prolong survival.
